Literature DB >> 11843282

Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.

Takahiro Okamoto, Masaya Okada, Takeshi Wakae, Ako Mori, Hiroyuki Takatsuka, Eizo Kakishita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11843282     DOI： 10.1007/bf02981990

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis.

Authors:  Y Xue; D Lu; Y Guo; B Lin
Journal:  Leuk Res       Date:  1992-11       Impact factor: 3.156

2.  Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.

Authors:  J E Rubnitz; B M Camitta; H Mahmoud; S C Raimondi; A J Carroll; M J Borowitz; J J Shuster; M P Link; D J Pullen; J R Downing; F G Behm; C H Pui
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma.

Authors:  T Okamoto; Y Nishimura; S Yamada; S Yamada; T Itoh; A Mori; K Saheki; M Okada; H Takatsuka; H Wada; A Tamura; Y Fujimori; E Kakishita
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

4.  Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group.

Authors:  Y Kagami; Y Ariyoshi; A Horiuchi; A Kanamaru; Y Kano; T Naoe; M Oguro; R Ohno; K Sampi; S Shirakawa; T Masaoka; H Furue
Journal:  Int J Hematol       Date:  1996-10       Impact factor: 2.490

5.  Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR.

Authors:  G Mitterbauer; C Zimmer; C Fonatsch; O Haas; R Thalhammer-Scherrer; I Schwarzinger; P Kalhs; U Jaeger; K Lechner; C Mannhalter
Journal:  Leukemia       Date:  1999-10       Impact factor: 11.528

6.  Acute myeloid leukaemia after treatment with razoxane.

Authors:  E A Caffrey; M G Daker; J J Horton
Journal:  Br J Dermatol       Date:  1985-08       Impact factor: 9.302

7.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.

Authors:  C H Pui; R C Ribeiro; M L Hancock; G K Rivera; W E Evans; S C Raimondi; D R Head; F G Behm; M H Mahmoud; J T Sandlund
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

8.  Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.

Authors:  N J Winick; R W McKenna; J J Shuster; N R Schneider; M J Borowitz; W P Bowman; D Jacaruso; B A Kamen; G R Buchanan
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

9.  Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.

Authors:  M K Andersen; B Johansson; S O Larsen; J Pedersen-Bjergaard
Journal:  Haematologica       Date:  1998-06       Impact factor: 9.941
  9 in total
  1 in total

1.  Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review.

Authors:  Naoki Shimada; Nobuhiro Ohno; Ryuji Tanosaki; Shigeo Fuji; Yuhko Suzuki; Koichiro Yuji; Kaoru Uchimaru; Arinobu Tojo
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.